IGF1R vaccine / Sequencio Therapeutics - LARVOL DELTA

Vaccine targeting IGF1R induces neutralizing antibody and robust anti-tumor activity in a syngeneic mouse colon cancer model (AACR 2026) - "In the anti-tumor study using the MC38 model, these two IGF1R vaccines suppressed the growth of tumors by 62% and 61%, respectively, at the study endpoint compared to controls (p<0.01).Conclusions In summary, these findings establish proof-of-concept that IGF1R-targeting vaccines can elicit neutralizing antibodies that block IGF1 binding to IGF1R, thereby inhibiting the growth of tumors where IGF/IGF1R signalling plays critical roles. This result supports further investigation and optimization to improve these IGF1R vaccines to treat cancers dependent on IGF/IGF1R signalling."

Preclinical • Colon Cancer • Colorectal Cancer • Oncology • Solid Tumor • IGF1 • IGF1R